Eli Lilly Commits Over $20B to Acquisitions, Acquires Seattle Biotech for $1.5B
LLY•Eli Lilly has announced over $20 billion in acquisitions this year, including up to $7.8 billion for Centessa, $7 billion for Kelonia and $3.8 billion for three vaccine developers. It also agreed to pay $1.5 billion for a Bothell biotech to develop a next-generation shingles vaccine.
1. Record Year-to-Date Acquisitions
Eli Lilly has committed over $20 billion to acquisitions so far in 2026, marking its highest annual spending on deals, including all milestone payments. This spending level surpasses previous records and underscores the company’s aggressive push beyond its obesity and diabetes franchises.
2. Key Transactions Completed
Recent agreements include up to $7.8 billion for sleep drugmaker Centessa Pharmaceuticals, $7 billion for cancer developer Kelonia Therapeutics, and $3.8 billion for three vaccine developers. Additionally, Lilly agreed to pay $1.5 billion for a Bothell, Washington biotech focused on a next-generation shingles vaccine.
3. Funding and Financial Impact
The acquisitions are largely funded by profits from Mounjaro and Zepbound, while Lilly maintains a strong balance sheet. Shares rose 1.1% on the acquisition news, reflecting investor confidence in the company’s capital deployment strategy.
4. Strategic Rationale and Future Outlook
Lilly aims to diversify its pipeline by targeting early-stage assets in oncology, gene therapy and vaccines, seeking to avoid past pitfalls such as the loss of Prozac patent exclusivity. Executives report evaluating at least ten potential deals weekly to build sustainable growth beyond current blockbusters.
